Tribute Pharmaceuticals Canada (SLRXF) 8-K Stellar Pharmaceuticals Announces Record Second Quarter Revenues

Exhibit 99.1

Press Release Source: Stellar Pharmaceuticals Inc.

STELLAR PHARMACEUTICALS ANNOUNCES RECORD SECOND QUARTER REVENUES

AND PROFITABILITY FOR THE FIRST HALF

London, Ontario – August 5, 2009– Stellar Pharmaceuticals Inc. ("Stellar" or the "Company") (OTCBB:SLXCF)a Canadian pharmaceutical developer and marketer of high quality, cost effective products for select health care markets, today announced that its second quarter revenues increased by 65.8% to $1,074,300 compared to $647,900 for the same period last year and that the Company had a profit of $164,700 for the quarter compared to a loss of $68,000 in the second quarter of 2008. This is the third consecutive quarter that the Company has shown a profit.

For the six month period ended June 30, 2009 Stellar’s total revenues increased by 57.1% to $1,846,800 compared to $1,175,300 for the same period in 2008. Canadian sales for NeoVisc and Uracyst were up by 22.2% and 21.9% respectively for the period. International sale increased by 121.4% for this period as the Company’s Europeanpartners continue to gain traction with both NeoVisc and Uracyst sales.  The Company showed a profit of $189,900 for the first half of 2009 compared to a loss of $166,800 over the same period in 2008.

Peter Riehl, Stellar’s President and CEO, stated, “This is the strongest second quarter in the Company’s history, with revenues up in all markets. We are very pleased to show profitability for the quarter and on a year-to-date basis, this currently puts the Company in a good position for strong operating results for the end of 2009. Besides these encouraging results, it has also been a very active quarter in other areas; Watson Pharmaceuticals received a conditional IDE from the FDA and has now started a pilot clinical trial at a number of centers in the USA, the Company also launched its NeoVisc Single Dose (one injection) in mid June and we are very pleased with initial sales genereated. In addition, the Company continues to actively search for new partners to out-license its products to around the world. It is very rewarding to see this growth and escalating business develop ment activities, given the challenging economic times.”

About Stellar Pharmaceuticals Inc.

Stellar has developed and is marketing direct in Canada and in countries around the world through out-license agreements two products based on its core polysaccharide technology:  NeoVisc®, for the treatment of osteoarthritis; and Uracyst®, its patented technology for treatment of interstitial cystitis/painful bladder syndrome an inflammatory disease of the urinary bladder wall.  Stellar also has in-licensing agreement for the distribution and sale of NMP22® BladderChek®, a proteomics-based diagnostic test for the diagnosis and monitoring of bladder cancer.

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of risks and uncertainties impacting the Company's business including increased competition; the ability of the Company to expand its operations, to attract and retain qualified professionals, technological obsolescence; general economic conditions; and other risks detailed from time to time in the Company's filings.

For More Information Please Contact:

Stellar Pharmaceuticals Inc.		Arnold Tenney
Peter Riehl	or	(416) 587-3200
President & CEO
(800) 639-0643 or (519) 434-1540
email: Corpinfo@StellarPharma.com

STELLAR PHARMACEUTICALS INC.

CONDENSED BALANCE SHEETS

(Expressed in Canadian Dollars)

	As at June 30, 2009			As at December 31, 2008
	(Unaudited)			(Audited)
ASSETS
CURRENT
Cash and cash equivalents	$	1,882,040		$	2,105,966
Accounts receivable, net of allowance $nil (2008 - $nil)		676,827			549,055
Inventories		651,296			364,551
Taxes recoverable		205,885			212,445
Loan receivable		18,369			18,369
Prepaids, deposits and sundry receivables		276,634			130,515
		3,711,051			3,380,901
PROPERTY, PLANT AND EQUIPMENT		1,248,699			1,270,257
OTHER ASSETS		91,048			65,495
	$	5,050,798		$	4,716,653
LIABILITIES
CURRENT
Accounts payable	$	183,684		$	173,812
Accrued liabilities		339,794			186,201
Deferred revenues		3,850			1,749
		527,328			361,762
CONTINGENCIES AND COMMITMENTS
SHAREHOLDERS’ EQUITY
CAPITAL STOCK
AUTHORIZED
Unlimited Non-voting, convertible, redeemable, and retractable preferred shares with no par value
Unlimited  Common shares with no par value
ISSUED
23,495,040 Common shares (2008 – 23,702,540)		8,188,486			8,261,403
Nil - Treasury shares (2008 – (147,500))		––			(51,625	)
Additional paid-in capital for cancelled common shares		2,329			2,329
Additional paid-in capital options - outstanding		35,965			35,965
– expired		722,372			722,372
		8,949,152			8,970,444
DEFICIT		(4,425,682	)		(4,615,553	)
		4,523,470			4,354,891
	$	5,050,798		$	4,716,653

STELLAR PHARMACEUTICALS INC.

CONDENSED INTERIM STATEMENTS OF OPERATIONS

AND COMPREHENSIVE LOSS AND DEFICIT

(Expressed in Canadian Dollars)

(Unaudited)

	For the Three Month Period						For the Six Month Period
	Ended June 30						Ended June 30
	2009			2008			2009			2008
PRODUCT SALES	$	914,126		$	645,535		$	1,458,545		$	974,991
COST OF PRODUCTS SOLD		333,082			148,937			488,034			260,332
MARGIN ON PRODUCTS SOLD		581,044			496,598			970,511			714,659
ROYALTY AND LICENSING REVENUES		160,168			2,400			388,265			200,356
GROSS PROFIT		741,212			498,998			1,358,776			915,015
EXPENSES
Selling, general and administrative		562,941			551,893			1,140,996			1,042,885
Research and development		1,803			4,424			7,411			58,242
Amortization (non-manufacturing property, plant and equipment)		13,703			30,044			27,401			60,426
		578,447			586,361			1,175,808			1,130,269
INCOME (LOSS) FROM OPERATIONS		162,765			(87,363	)		182,968			(215,254	)
INTEREST AND OTHER INCOME		1,929			19,349			6,903			48,423
NET INCOME (LOSS) AND COMPREHENSIVE
INCOME (LOSS) FOR THE PERIOD		164,694			(68,014	)		189,871			(166,831	)
DEFICIT,beginning of period		(4,590,376	)		(4,675,438	)		(4,615,553	)		(4,576,621	)
Effect of repurchase and cancellation of
Common Shares		––			(2,933	)		––			(2,933	)
DEFICIT,end of period	$	(4,425,682	)	$	(4,746,385	)	$	(4,425,682	)	$	(4,746,385	)
EARNINGS (LOSS) PER SHARE $	$	0.01		$	(0.00	)	$	0.01		$	(0.01	)
WEIGHTED AVERAGE NUMBER OF
COMMON SHARES OUTSTANDING		23,495,040			23,755,759			23,816,387			23,788,919

STELLAR PHARMACEUTICALS INC.

CONDENSED INTERIM STATEMENTS OF CASH FLOWS

(Expressed in Canadian Dollars)

(Unaudited)

	For the Three Month Period						For the Six Month Period
	Ended June 30						Ended June 30
	2009			2008			2009			2008
CASH FLOWS USED IN OPERATING ACTIVITIES -
Net income (loss) for the period	$	164,694		$	(68,014	)	$	189,871		$	(166,831	)
Items not affecting cash
Amortization		33,117			30,044			68,112			60,426
Unrealized foreign exchange (gain) loss		19,128			(7,912	)		20,523			2,317
Issuance of equity instruments for services rendered		––			7,538			––			13,125
Change in non-cash operating asset and liabilities		(593,295	)		2,788			(390,251	)		(109,397	)
CASH FLOWS USED IN OPERATING ACTIVITIES		(376,356	)		(35,556	)		(111,745	)		(200,360	)
CASH FLOWS USED IN INVESTING ACTIVITIES -
Additions to property, plant and equipment		(43,938	)		(177,971	)		(44,135	)		(193,877	)
Increase to other assets		(19,274	)		––			(26,231	)		(6,063	)
CASH FLOWS USED IN INVESTING ACTIVITIES		(63,212	)		(177,971	)		(70,366	)		(199,940	)
CASH FLOWS USED IN FINANCING ACTIVITIES -
Repurchase of common shares for cash		––			(43,655	)		(21,292	)		(43,655	)
CASH FLOWS USED IN FINANCING ACTIVITIES		––			(43,655	)		(21,292	)		(43,655	)
EFFECT OF EXCHANGE RATES ON CASH HELD IN
FOREIGN CURRENCY		(19,127	)		7,910			(20,523	)		(2,315	)
CHANGE IN CASH AND CASH EQUIVALENTS		(458,695	)		(249,272	)		(223,926	)		(446,270	)
CASH AND CASH EQUIVALENTS,
Beginning of period		2,340,735			3,014,128			2,105,966			3,211,126
CASH AND CASH EQUIVALENTS,
End of period	$	1,882,040		$	2,764,856		$	1,882,040		$	2,764,856

######